UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Edwards Lifesciences Corporation $EW

Posted by Brenda Bartman on Aug 31st, 2026

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 0.6% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 5,488,643 shares of the medical research company’s stock after buying an additional 30,495 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.95% of Edwards Lifesciences worth $496,503,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in EW. Rehmann Capital Advisory Group grew its holdings in Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after acquiring an additional 130 shares in the last quarter. McIlrath & Eck LLC increased its holdings in Edwards Lifesciences by 14.6% in the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock valued at $90,000 after buying an additional 135 shares during the last quarter. Quadrant Capital Group LLC increased its holdings in Edwards Lifesciences by 0.9% in the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after buying an additional 136 shares during the last quarter. Stephens Inc. AR raised its stake in Edwards Lifesciences by 5.4% in the fourth quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock valued at $239,000 after buying an additional 144 shares in the last quarter. Finally, Composition Wealth LLC lifted its holdings in Edwards Lifesciences by 1.6% during the 4th quarter. Composition Wealth LLC now owns 9,331 shares of the medical research company’s stock worth $795,000 after buying an additional 147 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Down 0.0%

Shares of NYSE:EW opened at $90.19 on Monday. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The stock has a market cap of $51.93 billion, a P/E ratio of 51.83, a P/E/G ratio of 2.37 and a beta of 0.85. The firm has a fifty day moving average price of $89.54 and a 200 day moving average price of $85.08.

Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same period in the prior year, the company earned $0.67 earnings per share. The business’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. UBS Group began coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $110.00 price target on the stock. Truist Financial boosted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, Royal Bank Of Canada raised their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Read Our Latest Analysis on Edwards Lifesciences

Insider Activity at Edwards Lifesciences

In other news, VP Annette Bruls sold 2,644 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 4,501 shares of company stock valued at $408,213. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.